Imatinib-d3 (hydrochloride)

Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

Product Specifications

CAS Number

[1134803-18-1]

Product Name Alternative

STI571-d3 (hydrochloride) ; CGP-57148B-d3 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

Autophagy; Bcr-Abl; c-Kit; PDGFR; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

95.19

Solubility

10 mM in DMSO|DMSO : 12.5mg/mL (ultrasonic) |H2O : 10mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=C(C=C1)CN2CCN(CC2)C([2H])([2H])[2H])NC3=CC=C(C)C(NC4=NC=CC(C5=CN=CC=C5)=N4)=C3

Molecular Formula

C29H28D3N7O

Molecular Weight

496.62

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.|[3]Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90 (19) :8924‐8933. Published 2016 Sep 12.